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Extracellular adenosine 5'-triphosphate and lipopolysaccharide induce 
interleukin-1β release in canine blood 
Abstract 
Binding of extracellular adenosine 5′-triphosphate (ATP) or lipopolysaccharide (LPS) to the damage-
associated molecular pattern receptor P2X7 or the pathogen-associated molecular pattern receptor Toll-
like receptor (TLR)4, respectively, can induce the release of the pleiotropic cytokine interleukin (IL)-1β in 
humans and mice. However, the release of IL-1β in dogs remains poorly defined. Using a canine IL-1β 
enzyme-linked immunosorbent assay, this study investigated whether ATP or LPS could induce IL-1β 
release in a canine blood-based assay. Short-term incubations (30 min) with ATP induced IL-1β release in 
LPS-primed canine blood, and this process could be near-completely impaired by the P2X7 antagonist, 
A438079. In contrast, ATP failed to induce IL-1β release from blood not primed with LPS. ATP-induced 
IL-1β release was observed with LPS-primed blood from eight different pedigrees or cross breeds. Long-
term incubations (24 h) with LPS induced IL-1β release in canine blood in a concentration-dependent 
manner. This process was not altered by co-incubation with A438079. LPS-induced IL-1β release was 
observed with blood from 10 different pedigrees or cross breeds. These results demonstrate that both 
extracellular ATP and LPS can induce IL-1β release in dogs, and that ATP- but not LPS-induced IL-1β 
release in blood is dependent on P2X7 activation. These findings support the role of both P2X7 and TLR4 
in IL-1β release in dogs. 
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Abstract	  
Binding	  of	   extracellular	  adenosine	  5’-­‐triphosphate	   (ATP)	  or	   lipopolysaccharide	   (LPS)	   to	   the	  
damage-­‐associated	   molecular	   pattern	   receptor	   P2X7	   or	   the	   pathogen-­‐associated	   molecular	  
pattern	   receptor	   Toll-­‐like	   receptor	   (TLR)4,	   respectively	   can	   induce	   the	   release	   of	   the	  
pleiotropic	  cytokine	  interleukin	  (IL)-­‐1β	  in	  humans	  and	  mice.	  However,	  the	  release	  of	  IL-­‐1β	  in	  
dogs	  remains	  poorly	  defined.	  Using	  a	  canine	  IL-­‐1β	  enzyme-­‐linked	  immunosorbent	  assay,	  this	  
study	   investigated	  whether	  ATP	  or	   LPS	   could	   induce	   IL-­‐1β	   release	   in	   a	   canine	  blood-­‐based	  
assay.	  Short-­‐term	  incubations	  (30	  min)	  with	  ATP	  induced	  IL-­‐1β	  release	  in	  LPS-­‐primed	  canine	  
blood,	  and	  this	  process	  could	  be	  near-­‐completely	  impaired	  by	  the	  P2X7	  antagonist,	  A438079.	  
In	  contrast,	  ATP	  failed	  to	  induce	  IL-­‐1β	  release	  from	  blood	  not	  primed	  with	  LPS.	  ATP-­‐induced	  
IL-­‐1β	   release	  was	   observed	  with	   LPS-­‐primed	   blood	   from	   eight	   different	   pedigrees	   or	   cross	  
breeds.	   Long-­‐term	   incubations	   (24	   h)	  with	   LPS	   induced	   IL-­‐1β	   release	   in	   canine	   blood	   in	   a	  
concentration-­‐dependent	   manner.	   This	   process	   was	   not	   altered	   by	   co-­‐incubation	   with	  
A438079.	  LPS-­‐induced	  IL-­‐1β	  release	  was	  observed	  with	  blood	  from	  10	  different	  pedigrees	  or	  
cross	  breeds.	  These	  results	  demonstrate	  that	  both	  extracellular	  ATP	  and	  LPS	  can	  induce	  IL-­‐1β	  
release	   in	   dogs,	   and	   that	  ATP-­‐	   but	   not	   LPS-­‐induced	   IL-­‐1β	   release	   in	   blood	   is	   dependent	   on	  
P2X7	  activation.	  These	   findings	  support	   the	  role	  of	  both	  P2X7	  and	  TLR4	   in	   IL-­‐1β	  release	   in	  
dogs.	  
	  
Keywords:	   damage-­‐associated	   molecular	   pattern	   receptor;	   purinergic	   receptor;	   pathogen-­‐
associated	  molecular	  pattern	  receptor;	  Toll-­‐like	  receptor;	  interleukin-­‐1β;	  dog	  
	  
Abbreviations:	   ATP,	   adenosine	   5’-­‐triphosphate;	   ELISA,	   enzyme-­‐linked	   immunosorbent	  
assay;	   IL,	   interleukin;	   LPS,	   lipopolysaccharide;	   PBMCs,	   peripheral	   blood	  mononuclear	   cells;	  
TLR,	  Toll-­‐like	  receptor.	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1.	  Introduction	  
	  
Interleukin	   (IL)-­‐1β	   (or	   IL-­‐IF2)	   is	   a	   pleiotropic	   cytokine	   predominately	   produced	   by	  
monocytes	   and	  macrophages,	   and	   has	   key	   roles	   in	   immunity,	   inflammation,	   hematopoiesis	  
and	  metabolism	  (Dinarello,	  2011).	  As	  a	  result,	  IL-­‐1β	  has	  emerged	  as	  a	  promising	  therapeutic	  
target	   for	  treating	  various	   local	  and	  systemic	   inflammatory	  conditions	   in	  humans	  (Dinarello	  
et	  al.,	  2012).	  IL-­‐1β	  is	  also	  expressed	  in	  dogs	  (Jalilian	  et	  al.,	  2012b),	  however	  knowledge	  of	  IL-­‐
1β	  in	  canine	  biology	  is	  largely	  limited	  to	  a	  small	  number	  of	  mRNA	  expression	  studies,	  where	  
IL-­‐1β	  has	  been	   reported	   to	  be	  up-­‐regulated	   in	   either	   infectious,	  musculoskeletal,	   cardiac	  or	  
respiratory	  disorders	  (Chen	  et	  al.,	  2012;	  Kiczak	  et	  al.,	  2008;	  Maccoux	  et	  al.,	  2007;	  Unver	  et	  al.,	  
2006).	   More	   recently,	   increased	   IL-­‐1β	   release	   has	   been	   observed	   in	   canine	   inflammatory	  
disorders	  of	  the	  bowel	  and	  eye	  (Maeda	  et	  al.,	  2012;	  Wichayacoop	  et	  al.,	  2009).	  Nevertheless	  
very	   little	   is	   known	   about	   the	  mechanisms	   involved	   in	   IL-­‐1β	   release	   in	   dogs.	   Thus,	   further	  
information	  regarding	  canine	  IL-­‐1β	  and	  its	  release	  is	  required	  to	  understand	  the	  role	  of	  this	  
cytokine	  in	  canine	  biology	  and	  to	  translate	  any	  potential	  therapeutic	  benefits	  of	  targeting	  IL-­‐
1β	  in	  humans	  to	  dogs.	  
IL-­‐1β	   is	   not	   constitutively	   expressed	   in	   monocytes,	   but	   is	   upregulated	   following	  
exposure	   of	   cells	   to	   pro-­‐inflammatory	   mediators	   including	   lipopolysaccharide	   (LPS)	  
(Dinarello,	   1996),	   a	   process	   referred	   to	   as	   priming.	   In	   humans	   and	  mice,	   LPS	   binds	   to	   the	  
pathogen-­‐associated	   molecular	   pattern	   receptor	   Toll-­‐like	   receptor	   (TLR)4	   to	   induce	   IL-­‐1β	  
expression	   and	   synthesis	   in	   monocytes	   (Hoshino	   et	   al.,	   1999;	   Medzhitov	   et	   al.,	   1997).	  
Incubation	  with	   LPS	   also	   induces	   the	   expression	   of	   NALP3	   (or	  NLRP3)	   (Bauernfeind	   et	   al.,	  
2009),	  which	  assembles	  with	  caspase-­‐1	   to	   form	  the	  NALP3	   inflammasome	  to	  mediate	   IL-­‐1β	  
maturation	  and	  release	  (Agostini	  et	  al.,	  2004).	  Although	  LPS	  appears	  sufficient	  to	  induce	  the	  
slow	  (24	  h)	  release	  of	  IL-­‐1β	  (Lepe-­‐Zuniga	  and	  Gery,	  1984),	  a	  second	  signal,	  such	  as	  activation	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of	   the	   damage-­‐associated	   molecular	   pattern	   receptor	   P2X7	   by	   its	   ligand	   extracellular	  
adenosine	  5’-­‐triphosphate	  (ATP),	  is	  required	  for	  the	  rapid	  (30	  min)	  release	  of	  IL-­‐1β	  following	  
its	  synthesis	  (Grahames	  et	  al.,	  1999;	  Solle	  et	  al.,	  2001).	  P2X7	  activation	  induces	  IL-­‐1β	  release	  
from	   LPS-­‐primed	   canine	  monocytes	   (Jalilian	   et	   al.,	   2012a)	   and	   in	   LPS-­‐primed	   canine	   blood	  
(Roman	   et	   al.,	   2009),	   however	   it	   remains	   unknown	   if	   LPS	   priming	   is	   required	   for	   P2X7-­‐
induced	  IL-­‐1β	  release	  in	  dogs.	  In	  human	  monocytes,	  LPS	  can	  induce	  the	  slow	  release	  of	  IL-­‐1β	  
by	   both	   P2X7-­‐dependent	   (Netea	   et	   al.,	   2009;	   Piccini	   et	   al.,	   2008)	   and	   P2X7-­‐independent	  
mechanisms	   (Ward	   et	   al.,	   2010).	   LPS	   can	   also	   induce	   IL-­‐1β	   release	   from	   canine	   peripheral	  
blood	  mononuclear	  cells	  	  (PBMCs)	  (Baggio	  et	  al.,	  2005),	  but	  whether	  this	  process	  is	  dependent	  
on	   P2X7	   activation	   remains	   to	   be	   established.	   Blood-­‐based	   assays	   are	   commonly	   used	   to	  
study	  cytokine	  release	  ex	  vivo,	  as	  they	  require	  fewer	  manipulations	  compared	  to	  assays	  that	  
use	  purified	  blood	  leukocytes,	  and	  thereby	  limit	  the	  inadvertent	  activation	  of	  cells.	  Therefore	  
using	  a	  blood-­‐based	  assay	  the	  current	  study	   investigated	   first,	   if	  canine	  P2X7-­‐induced	  IL-­‐1β	  
release	   requires	  LPS	  priming	   and	   second,	   if	   LPS	   is	   sufficient	   to	   induce	   canine	   IL-­‐1β	   release	  
and	  if	  so,	  whether	  this	  process	  involves	  P2X7	  activation.	  
	  




RPMI-­‐1640	   medium	   and	   penicillin-­‐streptomycin-­‐glutamine	   were	   from	   Invitrogen	  
(Grand	   Island,	  NJ).	  LPS	  (Escherichia	  Coli	   serotype	  055:B5),	  ATP	  (BioXtra)	  and	  bovine	  serum	  
albumin	  (fatty	  acid	  and	  globulin	  free)	  were	  from	  Sigma	  Chemical	  Co	  (St	  Louis,	  MO).	  A438079	  
was	  from	  Tocris	  Bioscience	  (Ellisville,	  MO).	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2.2.	  Blood-­‐based	  IL-­‐1β	  release	  assay	  
	  
Peripheral	  blood	  was	   collected	   into	  VACUETTE®	   lithium	  heparin	   tubes	   (Greiner	  Bio-­‐
One,	   Frickenheisen,	   Germany)	   from	   either	   11	   pedigree	   or	   four	   cross	   breed	   dogs	   with	  
informed,	   signed	   consent	   of	   pet	   owners,	   and	   with	   the	   approval	   of	   the	   University	   of	  
Wollongong	  Ethics	  Committee	  (Wollongong,	  Australia).	  Eleven	  of	  the	  animals	  were	  healthy	  at	  
the	   time	  of	   blood	   collection,	  while	   four	  presented	  with	  minor	  health	  problems	   (an	  Alaskan	  
Malamute	  with	  a	  fractured	  carnassial	  tooth,	  a	  Maltese	  and	  Shih	  Tzu	  cross	  with	  dental	  disease,	  
a	   Labrador	   Retriever	   with	   otitis	   externa	   and	   a	   Shar	   Pei	   with	   bilateral	   otitis	   externa).	   All	  
animals	  had	  no	  evidence	  of	  fever	  at	  the	  time	  of	  blood	  collection.	  
The	  release	  of	  IL-­‐1β	  from	  cells	  in	  blood	  was	  performed	  as	  described	  (Perregaux	  et	  al.,	  
2000),	  with	  minor	  modification.	   Briefly,	   100	  µL	   of	   canine	   blood	   and	   100	  µL	   of	   RPMI-­‐1640	  
medium	  (containing	  10	  mM	  HEPES,	  100	  U/mL	  penicillin,	  100	  µg/mL	  streptomycin	  and	  2	  mM	  
L-­‐glutamine)	  were	  combined	  into	  flat-­‐bottomed	  96-­‐well	  plates	  (Greiner	  Bio-­‐One).	  In	  the	  first	  
series	  of	  experiments,	  diluted	  blood	  was	  incubated	  in	  the	  absence	  or	  presence	  of	  0.1	  µg/mL	  
LPS	  for	  2	  h	  at	  37oC/5%	  CO2,	  and	  then	  in	  the	  absence	  or	  presence	  of	  6	  mM	  ATP	  for	  a	  further	  30	  
min.	  In	  some	  experiments,	  50	  µM	  A438079	  was	  added	  during	  the	  final	  15	  min	  of	  the	  2	  h	  LPS	  
incubation	   before	   ATP	   addition.	   In	   the	   second	   series	   of	   experiments,	   diluted	   blood	   was	  
incubated	  with	  0-­‐10	  µg/mL	  LPS	   in	   the	   absence	   or	   presence	   of	   50	  µM	  A438079	   for	   24	  h	   at	  
37oC/5%	  CO2.	  Samples	  from	  each	  series	  were	  centrifuged	  at	  700xg	   for	  10	  min,	  and	  the	  cell-­‐
free	  supernatants	  stored	  at	  -­‐80oC	  until	  required.	  The	  amount	  of	  IL-­‐1β	  in	  cell-­‐free	  supernatants	  
was	  quantified	  using	  a	  Canine	   IL-­‐1β	  VetSetTM	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	  
Development	  Kit	  and	  ELISA	  Accessory	  Pack	  (both	  Kingfisher	  Biotech,	  St.	  Paul,	  MN)	  with	  4%	  
bovine	  serum	  albumin	  in	  Dulbecco’s	  phosphate-­‐buffered	  saline	  used	  as	  the	  Assay	  Diluent	  as	  
per	  the	  manufacturer's	  instructions.	  
	   6	  
	  
2.3.	  Statistical	  analysis	  
	  
Differences	   between	   groups	   were	   compared	   using	   a	   one-­‐way	   analysis	   of	   variance	  
(using	  Tukey's	  post	  test).	  
	  
3.	  Results	  and	  discussion	  
	  
3.1	  P2X7	  activation	  induces	  IL-­‐1β	  release	  in	  canine	  blood	  and	  requires	  priming	  with	  LPS	  
	  
Our	  group	  and	  one	  other	  have	  previously	  demonstrated	  that	  P2X7	  activation	  induces	  
canine	   IL-­‐1β	   release	   from	   LPS-­‐primed	   monocytes	   (Jalilian	   et	   al.,	   2012a)	   or	   in	   LPS-­‐primed	  
blood	  (Roman	  et	  al.,	  2009),	  however	  it	  remains	  unknown	  if	  LPS	  priming	  is	  required	  for	  P2X7-­‐
induced	   IL-­‐1β	   release	   in	   dogs.	   Therefore,	   to	   confirm	   that	   P2X7	   activation	   induces	   IL-­‐1β	  
release	   in	   blood,	   LPS-­‐primed	   blood	  was	   incubated	   in	   the	   absence	   or	   presence	   of	   the	   P2X7	  
antagonist	  A438079	  (Nelson	  et	  al.,	  2006)	  before	  30	  min	  incubation	  in	  the	  absence	  or	  presence	  
of	   ATP,	   and	   measurement	   of	   IL-­‐1β	   in	   cell-­‐free	   supernatants	   by	   ELISA.	   Consistent	   with	  
previous	  findings	  (Roman	  et	  al.,	  2009),	  ATP	  in	  the	  absence	  of	  P2X7	  antagonist	  induced	  IL-­‐1β	  
release	  in	  LPS-­‐primed	  blood,	  which	  was	  on	  average	  four-­‐fold	  greater	  than	  that	  of	  LPS-­‐primed	  
blood	   incubated	   in	   the	   absence	  of	  ATP,	  which	  was	  minimal	   (Fig.	   1A).	   In	   LPS-­‐primed	  blood,	  
pre-­‐incubation	   with	   A438079	   impaired	   ATP-­‐induced	   IL-­‐1β	   release	   by	   97	   ±	   9%	   (mean	   ±	  
standard	  deviation)	  compared	  to	  ATP-­‐induced	  IL-­‐1β	  release	  in	  the	  absence	  of	  A438079	  (Fig.	  
1A).	   In	   contrast,	   A438079	   in	   the	   absence	   of	   ATP	   had	   no	   significant	   effect	   on	   IL-­‐1β	   release	  
compared	   to	   IL-­‐1β	   release	   in	   the	   absence	   of	   both	  A438079	   and	  ATP	   (Fig.	   1A).	   Collectively,	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these	  results	  indicate	  that	  ATP	  induces	  IL-­‐1β	  release	  in	  LPS-­‐primed	  canine	  blood	  and	  that	  this	  
process	  is	  mediated	  by	  P2X7	  activation.	  
To	   determine	   whether	   P2X7-­‐induced	   IL-­‐1β	   release	   in	   canine	   blood	   requires	   LPS	  
priming,	   blood	  was	  pre-­‐incubated	   in	   the	   absence	  or	  presence	  of	   LPS	   for	  2	  h	  before	  30	  min	  
incubation	  in	  the	  absence	  or	  presence	  of	  ATP.	  Similar	  to	  above	  (Fig.	  1A),	  ATP	  induced	  IL-­‐1β	  
release	  in	  LPS-­‐primed	  blood,	  which	  was	  on	  average	  five-­‐fold	  greater	  than	  that	  of	  LPS-­‐primed	  
blood	  in	  the	  absence	  of	  ATP,	  which	  again	  was	  minimal	  (Fig.	  1B).	  Notably,	  ATP	  was	  unable	  to	  
increase	   IL-­‐1β	   release	   in	   blood	   in	   the	   absence	   of	   LPS	   compared	   to	   blood	   incubated	   in	   the	  
absence	  of	  both	  LPS	  and	  ATP,	  and	  was	  significantly	  lower	  than	  ATP-­‐induced	  IL-­‐1β	  release	  in	  
LPS-­‐primed	   blood	   (Fig.	   1B).	   Thus,	   these	   results	   indicate	   that	   LPS-­‐priming	   is	   necessary	   for	  
P2X7-­‐induced	  IL-­‐1β	  release	  in	  canine	  blood.	  
Combination	  of	  the	  above	  IL-­‐1β	  release	  data	  from	  LPS-­‐primed	  blood	  incubated	  in	  the	  
absence	  or	  presence	  of	  ATP	  (Fig.	  1A	  and	  B),	  with	  results	  from	  four	  other	  dogs	  (three	  Labrador	  
Retrievers,	  and	  a	  Maltese	  and	  Shih	  Tzu	  cross),	  demonstrates	  that	  P2X7	  activation	  induces	  IL-­‐
1β	  release	   in	  LPS-­‐primed	  blood	   from	  eight	  pedigrees	  or	  cross	  breeds	  other	   than	   the	  Beagle	  
(Fig.	  1C).	  On	  average,	  ATP	  induced	  a	  four-­‐fold	  increase	  in	  IL-­‐1β	  release	  in	  blood	  compared	  to	  
blood	   incubated	   in	   the	  absence	  of	  ATP	   (Fig.	  1C).	   Similar	   to	  our	  previous	   findings	  with	  LPS-­‐
primed	  canine	  monocytes	   (Jalilian	  et	  al.,	  2012a),	  P2X7-­‐induced	   IL-­‐1β	  release	   in	  LPS-­‐primed	  
blood	  varied	  between	  dogs	  (Fig.	  1).	  The	  cause	  of	  this	  variation	  remains	  unknown,	  but	  may	  be	  
due	  to	  differences	  in	  TLR4	  signalling,	  P2X7	  activation,	  NALP3	  inflammasome	  stimulation	  and	  
IL-­‐1β	   release.	   For	   example,	   single	   nucleotide	  polymorphisms	   in	   the	   canine	  TLR4	   gene	  have	  
been	   associated	   with	   inflammatory	   bowel	   disease	   in	   German	   Shepherds	   (Kathrani	   et	   al.,	  
2010),	  suggesting	  that	  differences	  in	  LPS	  priming	  as	  a	  result	  of	  such	  polymorphisms	  may	  also	  
influence	   IL-­‐1β	   production.	   Alternatively,	   single	   nucleotide	   polymorphisms	   in	   the	   human	  
P2RX7	   gene	   can	   significantly	   modulate	   P2X7-­‐induced	   IL-­‐1β	   release	   in	   LPS-­‐primed	   human	  
	   8	  
monocytes	   (Sluyter	  et	  al.,	  2004;	  Stokes	  et	  al.,	  2010),	   suggesting	   that	   the	   canine	  P2RX7	   gene	  
may	   also	   encode	   for	   polymorphisms	   that	  modify	   P2X7-­‐induced	   IL-­‐1β	   release	   in	   dogs.	   It	   is	  
unlikely	  that	  health	  status	  contributed	  to	  the	  variation	  in	  P2X7-­‐induced	  IL-­‐1β	  release	  between	  
dogs,	  as	  all	  dogs	  had	  no	  evidence	  of	   fever	  at	   the	   time	  of	  blood	  collection,	  and	   the	   four	  dogs	  
with	  minor	  health	  issues	  had	  IL-­‐1β	  release	  measurements	  equivalent	  to	  at	   least	  one	  healthy	  
dog.	  
	  
3.2	  LPS	  incubation	  is	  sufficient	  for	  IL-­‐1β	  release	  in	  canine	  blood	  
	  
The	  above	  data	  (Fig.	  1),	  indicates	  that	  incubation	  with	  LPS	  for	  2.5	  h	  induces	  negligible	  
to	   low	  amounts	  of	   IL-­‐1β	  release	   in	  canine	  blood.	   In	  contrast,	  24	  h	   incubation	  with	  1	  µg/mL	  
LPS	   induces	   IL-­‐1β	   release	   from	   isolated	   canine	   PBMCs	   (Baggio	   et	   al.,	   2005).	   Therefore,	   to	  
determine	   if	   incubation	  with	  LPS	  alone	   is	  sufficient	   to	   induce	   IL-­‐1β	  release	   in	  canine	  blood,	  
blood	  was	  incubated	  with	  increasing	  concentrations	  of	  LPS	  for	  24	  h,	  before	  measurement	  of	  
IL-­‐1β	   in	   cell-­‐free	   supernatants	  by	  ELISA.	   In	   the	  absence	  of	  LPS,	  24	  h	   incubation	   resulted	   in	  
negligible	  to	  low	  amounts	  of	  IL-­‐1β	  release	  (Fig.	  2A),	  similar	  to	  that	  observed	  after	  2.5	  h	  (Fig.	  
1B).	  In	  contrast,	  24	  h	  incubation	  with	  LPS	  induced	  IL-­‐1β	  release	  in	  a	  concentration-­‐dependent	  
manner,	  with	   an	   average	  16-­‐fold	   increase	   in	   IL-­‐1β	   release	  between	  no	  LPS	   and	   the	  highest	  
LPS	  concentration	  (10	  µg/mL)	  tested	  (Fig.	  2A).	  
Previous	  studies	  with	  human	  monocytes	  have	  implicated	  a	  role	  for	  ATP	  release	  and	  the	  
autocrine	   activation	   of	   P2X7	   in	   LPS-­‐induced	   IL-­‐1β	   release	   (Netea	   et	   al.,	   2009;	   Piccini	   et	   al.,	  
2008).	  Therefore,	  blood	  was	  incubated	  with	  0.1	  µg/mL	  LPS,	  the	  same	  concentration	  used	  for	  
the	   P2X7	   studies	   above	   (Fig.	   1),	   in	   the	   absence	   or	   presence	   of	  A438079.	   In	   contrast	   to	   the	  
near-­‐complete	   inhibition	   of	   ATP-­‐induced	   IL-­‐1β	   release	   by	   A438079	   above	   (Fig.	   1A),	   this	  
antagonist	  was	  unable	  to	  prevent	  LPS-­‐induced	  IL-­‐1β	  release	  over	  24	  h	  (Fig.	  2B).	  A438079	  in	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the	  absence	  of	  LPS	  also	  had	  no	  significant	  effect	  on	  IL-­‐1β	  release	  compared	  to	  IL-­‐1β	  release	  in	  
the	  absence	  of	  both	  A438079	  and	  LPS	  (Fig.	  2B).	  Collectively,	  these	  results	  indicate	  that	  LPS	  is	  
sufficient	  for	  IL-­‐1β	  release	  in	  canine	  blood	  and	  that	  this	  process	  does	  not	  involve	  ATP	  release	  
and	  the	  autocrine	  activation	  of	  P2X7	  as	  observed	  for	  LPS-­‐induced	  IL-­‐1β	  release	  from	  human	  
monocytes	  (Netea	  et	  al.,	  2009;	  Piccini	  et	  al.,	  2008).	  Nevertheless	  the	  possibility	  remains	  that	  
A438079	   has	   limited	   efficacy	   in	   24	   h	   incubations.	   This	   however	   is	   unlikely,	   as	   this	   same	  
antagonist	  has	  been	  shown	  in	  our	  laboratory	  to	  prevent	  P2X7-­‐induced	  death	  in	  lymphoid	  and	  
erythroid	  cells	  over	  the	  same	  time	  period	  (Constantinescu	  et	  al.,	  2010;	  Farrell	  et	  al.,	  2010).	  Of	  
note,	  incubation	  of	  human	  monocytes	  for	  24	  h	  with	  TLR	  agonists,	  including	  LPS,	  can	  result	  in	  
P2X7-­‐independent	  IL-­‐1β	  release	  (Ward	  et	  al.,	  2010),	  further	  supporting	  the	  concept	  that	  24	  h	  
incubation	  with	  LPS	  is	  sufficient	  for	  IL-­‐1β	  release	  in	  canine	  blood	  and	  that	  this	  process	  occurs	  
independently	  of	  P2X7.	  
Finally,	  combined	  data	  from	  blood	  primed	  with	  0.1	  µg/mL	  LPS	  (Fig.	  2A	  and	  B),	  or	  data	  
from	  blood	  primed	  with	  10	  µg/mL	  LPS	  (Fig.	  2A)	  combined	  with	  results	  using	  blood	  (primed	  
with	  10	  µg/mL	  LPS)	  from	  four	  other	  dogs	  (three	  Labrador	  Retrievers,	  and	  a	  Maltese	  and	  Shih	  
Tzu	  cross),	  demonstrates	  that	  24	  h	  incubation	  with	  LPS	  induces	  IL-­‐1β	  release	  in	  blood	  from	  
10	  pedigrees	  or	  cross	  breeds	  (Fig.	  2C	  and	  D).	  On	  average,	  0.1	  and	  10	  µg/mL	  LPS	  induced	  a	  12-­‐	  
and	  13-­‐fold	  increase	  in	  IL-­‐1β	  release	  in	  blood	  compared	  to	  blood	  incubated	  in	  the	  absence	  of	  
LPS	  (Fig.	  2C).	  Similar	  to	  P2X7-­‐induced	  IL-­‐1β	  release	  in	  LPS-­‐primed	  blood	  (Fig.	  1),	  LPS-­‐induced	  
IL-­‐1β	  release	  varied	  between	  dogs	  (Fig.	  2).	  Thereby	  supporting	  the	  concept	  that	  differences	  in	  
TLR4	   signalling,	   NALP3	   inflammasome	   stimulation	   and	   IL-­‐1β	   release	   exist	   between	   dogs.	  
Again	  it	  is	  unlikely	  that	  health	  status	  contributed	  to	  the	  variation	  in	  LPS-­‐induced	  IL-­‐1β	  release	  
between	  dogs,	   as	   all	   dogs	   had	  no	   evidence	   of	   fever	   at	   the	   time	  of	   blood	   collection,	   and	   the	  
three	  dogs	  with	  minor	  health	   issues	  had	   IL-­‐1β	   release	  measurements	   equivalent	   to	   at	   least	  
one	  healthy	  dog.	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3.3	  Conclusion	  
	  
The	  current	   study	   indicates	   that	  both	  extracellular	  ATP	  and	  LPS	   induce	  canine	   IL-­‐1β	  
release	  in	  blood.	  Although	  the	  cell	  type	  was	  not	  identified	  in	  our	  study,	  it	  is	  likely	  that	  IL-­‐1β	  
was	   released	   from	   monocytes,	   the	   main	   producers	   of	   IL-­‐1β	   in	   human	   blood	   (Allen	   et	   al.,	  
1992).	  Thus,	   the	  possibility	  remains	  that	  the	  variation	   in	  ATP-­‐	  or	  LPS-­‐induced	  IL-­‐1β	  release	  
between	  dogs	   reflects	  differences	   in	  blood	  monocyte	   counts,	  which	  were	  unavailable	  at	   the	  
time	   of	   study.	   It	   is	   also	   likely	   that	   both	   ATP-­‐	   and	   LPS-­‐induced	   IL-­‐1β	   release	   required	  
activation	   of	   the	   NALP3	   inflammasome.	   We	   have	   previously	   shown	   that	   both	   NALP3	   and	  
caspase-­‐1	   transcripts	   are	   present	   in	   canine	  monocytes	   (Jalilian	   et	   al.,	   2012a),	   while	   others	  
have	   shown	   that	   the	   caspase	   inhibitor	   z-­‐VAD	   impairs	   ATP-­‐induced	   IL-­‐1β	   release	   in	   LPS-­‐
primed	   blood	   of	   Beagles	   (Roman	   et	   al.,	   2009).	   The	   current	   study	   also	   indicates	   that	   both	  
extracellular	  ATP	  and	  LPS	  can	  induce	  IL-­‐1β	  release	  in	  blood	  from	  various	  breeds	  including	  the	  
Shar	  Pei.	  Of	  note,	  the	  Shar	  Pei	  can	  suffer	  from	  a	  recurring	  fever-­‐like	  a	  condition	  similar	  to	  that	  
of	  familial	  Mediterranean	  fever	  (Hayem,	  2013),	  a	  human	  condition	  that	  arises	  from	  a	  mutation	  
in	   the	   inflammasome-­‐related	   protein	   pyrin	   and	   results	   in	   elevated	   IL-­‐1β	   (Mansfield	   et	   al.,	  
2001).	  Although	  the	  amount	  of	  IL-­‐1β	  release	  in	  this	  Shar	  Pei,	  which	  had	  no	  reported	  history	  of	  
recurring	   fever,	   was	  within	   the	   range	   to	   that	   of	   the	   other	   dogs	   studied,	   to	   the	   best	   of	   our	  
knowledge	   this	   is	   the	   first	   observation	  of	   IL-­‐1β	  production	   in	   this	  breed,	  albeit	   in	   only	  one	  
dog.	  
In	   conclusion,	   these	   results	   demonstrate	   that	   both	   extracellular	   ATP	   and	   LPS	   can	  
induce	   IL-­‐1β	   release	   in	   dogs,	   and	   that	   ATP-­‐	   but	   not	   LPS-­‐induced	   IL-­‐1β	   release	   in	   blood	   is	  
mediated	  by	  P2X7.	  These	  findings	  support	  the	  role	  of	  both	  P2X7	  and	  TLR4	  in	  IL-­‐1β	  release	  in	  
dogs.	  Finally,	  these	  results	  suggest	  that	  further	  study	  of	  IL-­‐1β	  as	  a	  potential	  therapeutic	  target	  
in	  dogs	  is	  warranted.	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Fig.	  1.	  P2X7	  activation	  induces	  IL-­‐1β	  release	  in	  canine	  blood	  and	  requires	  priming	  with	  LPS.	  
(A)	  Blood	  diluted	  with	  an	  equal	  volume	  of	  RPMI-­‐1640	  medium	  was	  incubated	  in	  the	  presence	  
of	  0.1	  µg/mL	  LPS	  for	  2	  h	  at	  37oC.	  During	  the	  final	  15	  min	  of	  this	  2	  h	  incubation,	  samples	  were	  
incubated	   in	   the	   absence	   or	   presence	   of	   50	   µM	   A438079	   (A438).	   Samples	   were	   then	  
incubated	  for	  a	  further	  30	  min	  in	  the	  absence	  or	  presence	  of	  6	  mM	  ATP.	  (B)	  Blood	  diluted	  with	  
an	   equal	   volume	   of	   RPMI-­‐1640	   medium	   was	   incubated	   in	   the	   absence	   or	   presence	   of	   0.1	  
µg/mL	  LPS	  for	  2	  h	  at	  37oC,	  and	  then	  for	  a	  further	  30	  min	  in	  the	  absence	  or	  presence	  of	  6	  mM	  
ATP.	   (C)	   Blood	   diluted	  with	   an	   equal	   volume	   of	   RPMI-­‐1640	  medium	  was	   incubated	   in	   the	  
	   16	  
presence	  of	  0.1	  µg/mL	  LPS	   for	  2	  h	  at	  37oC,	  and	  then	   for	  a	   further	  30	  min	   in	   the	  absence	  or	  
presence	  of	  6	  mM	  ATP.	  (A-­‐C)	  Following	  a	  total	  incubation	  of	  2.5	  h,	  cell-­‐free	  supernatants	  were	  
collected	  and	  the	  amount	  of	  IL-­‐1β	  release	  determined	  by	  ELISA.	  Symbols	  represent	  individual	  
dogs;	   bars	   represent	   group	   means;	   *P<0.05,	   ***P<0.001	   compared	   to	   Control;	   ††P<0.01	  
compared	  to	  (A)	  LPS	  and	  ATP,	  or	  (B)	  LPS	  or	  ATP	  alone.	  (C)	  Maltese	  X	  Shih	  Tzu,	  Maltese	  and	  
Shih	  Tzu	  cross;	  Staffordshire	  Bull	  Terrier	  X,	  Staffordshire	  Bull	  Terrier	  and	  Australian	  Kelpie	  
cross.	  
	  
Fig.	  2.	  LPS	  incubation	  is	  sufficient	  for	  IL-­‐1β	  release	  in	  canine	  blood.	  (A,	  C	  and	  D)	  Blood	  diluted	  
with	  an	  equal	  volume	  of	  RPMI-­‐1640	  medium	  was	  incubated	  in	  the	  absence	  or	  presence	  of	  LPS	  
(as	  indicated)	  for	  24	  h	  at	  37oC.	  (B)	  Blood	  diluted	  with	  an	  equal	  volume	  of	  RPMI-­‐1640	  medium	  
was	  co-­‐incubated	  in	  the	  absence	  or	  presence	  of	  0.1	  µg/mL	  LPS	  and	  50	  µM	  A438079	  (A438)	  
for	  24	  h	  at	  37oC.	  (A-­‐D)	  Following	  24	  h	   incubation,	  cell-­‐free	  supernatants	  were	  collected	  and	  
the	   amount	  of	   IL-­‐1β	   release	  determined	  by	  ELISA.	   Symbols	   represent	   individual	   dogs;	   bars	  
represent	   group	   means;	   *P<0.05,	   **P<0.01,	   ***P<0.001	   compared	   to	   Control;	   †P<0.01	  
compared	  to	  A438079	  alone.	  (C	  and	  D)	  Boxer	  X	  Bull	  Terrier,	  Boxer	  and	  Bull	  Terrier	  cross;	  Bull	  
Mastiff	  X,	  Bull	  Mastiff	  cross;	  Maltese	  X	  Shih	  Tzu,	  Maltese	  and	  Shih	  Tzu	  cross;	  Staffordshire	  Bull	  
Terrier	  X,	  Staffordshire	  Bull	  Terrier	  and	  Australian	  Kelpie	  cross.	  


